Evidence map›Paper›PMID 31996670›Full record

ArticleNature communications2020

Modeling medulloblastoma in vivo and with human cerebellar organoids.

Claudio Ballabio, Marica Anderle, Matteo Gianesello, Chiara Lago, Evelina Miele, Marina Cardano, Giuseppe Aiello, Silvano Piazza, Davide Caron, Francesca Gianno and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Modeling pediatric brain tumors with human stem cells.Frontiers in cellular neuroscience · 2026
    Review
  18. Review
  19. Article
  20. Review

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Claudio Ballabio *Armenise-Harvard Laboratory of Brain Cancer, Department CIBIO, University of Trento, Via Sommarive 9, 38123, Trento, Italy.ORCID http://orcid.org/0000-0001-6632-1489
Marica Anderle *Armenise-Harvard Laboratory of Brain Cancer, Department CIBIO, University of Trento, Via Sommarive 9, 38123, Trento, Italy.
Matteo GianeselloArmenise-Harvard Laboratory of Brain Cancer, Department CIBIO, University of Trento, Via Sommarive 9, 38123, Trento, Italy.
Chiara LagoArmenise-Harvard Laboratory of Brain Cancer, Department CIBIO, University of Trento, Via Sommarive 9, 38123, Trento, Italy.
Evelina MieleDepartment of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Marina CardanoUniversity of Trento, Via Sommarive 9, 38123, Trento, Italy.ORCID http://orcid.org/0000-0003-0368-3196
Giuseppe AielloArmenise-Harvard Laboratory of Brain Cancer, Department CIBIO, University of Trento, Via Sommarive 9, 38123, Trento, Italy.
Silvano PiazzaUniversity of Trento, Via Sommarive 9, 38123, Trento, Italy.
Davide CaronArmenise-Harvard Laboratory of Brain Cancer, Department CIBIO, University of Trento, Via Sommarive 9, 38123, Trento, Italy.
Francesca GiannoDepartment of Radiologic, Oncologic and Anatomo Pathological Sciences, University Sapienza of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-6223-9952
Andrea CiolfiGenetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146, Rome, Italy.
Lucia PedaceDepartment of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Angela MastronuzziDepartment of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-4408-2373
Marco TartagliaGenetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146, Rome, Italy.
Franco LocatelliDepartment of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Elisabetta FerrettiDepartment of Experimental Medicine, Sapienza University, Rome, Italy.ORCID http://orcid.org/0000-0001-7265-6429
Felice GiangasperoDepartment of Radiologic, Oncologic and Anatomo Pathological Sciences, University Sapienza of Rome, Rome, Italy.
Luca TiberiArmenise-Harvard Laboratory of Brain Cancer, Department CIBIO, University of Trento, Via Sommarive 9, 38123, Trento, Italy. luca.tiberi@unitn.it.
University of Trento · ITBambino Gesù Children's Hospital · ITIstituto Neurologico Mediterraneo · ITSapienza University of Rome · IT

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) MFAG 2017 #19921Fondazione Cassa Di Risparmio Di Trento E Rovereto (Fondazione Caritro) 2019Giovanni Armenise-Harvard Foundation CDA 2016
6 · The paper itself

Abstract

Medulloblastoma (MB) is the most common malignant brain tumor in children and among the subtypes, Group 3 MB has the worst outcome. Here, we perform an in vivo, patient-specific screen leading to the identification of Otx2 and c-MYC as strong Group 3 MB inducers. We validated our findings in human cerebellar organoids where Otx2/c-MYC give rise to MB-like organoids harboring a DNA methylation signature that clusters with human Group 3 tumors. Furthermore, we show that SMARCA4 is able to reduce Otx2/c-MYC tumorigenic activity in vivo and in human cerebellar organoids while SMARCA4 T910M, a mutant form found in human MB patients, inhibits the wild-type protein function. Finally, treatment with Tazemetostat, a EZH2-specific inhibitor, reduces Otx2/c-MYC tumorigenesis in ex vivo culture and human cerebellar organoids. In conclusion, human cerebellar organoids can be efficiently used to understand the role of genes found altered in cancer patients and represent a reliable tool for developing personalized therapies.

Indexed as

BenzamidesBiphenyl CompoundsBrain NeoplasmsCarcinogenesisCell Line, TumorCerebellar NeoplasmsDNA HelicasesDNA MethylationEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticHumansMedulloblastomaMorpholinesNuclear ProteinsOrganoidsOtx Transcription FactorsBenzamidesBiphenyl CompoundsDNA HelicasesEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMorpholinesMYC protein, humanNuclear ProteinsOTX2 protein, humanOtx Transcription FactorsProto-Oncogene Proteins c-mycPyridonesSMARCA4 protein, humantazemetostatTranscription Factors

Identifiers

PMID31996670
PMCPMC6989674
OpenAlexW3004193882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.